Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 7:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 57 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Actual Body Weight Dosing Clear all
Active, not recruiting Phase 4 Interventional

Ketamine vs Lidocaine in Traumatic Rib Fractures

NCT04781673
View directory record Official record
Conditions
Rib Fractures, Rib Fracture Multiple, Rib Trauma
Interventions
Ketamine, Lidocaine
Drug
Lead sponsor
Brittany Hoyte
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 30, 2026, 7:46 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia

NCT00495079
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia (ALL)
Interventions
Marqibo® (vincristine sulfate liposomes injection)
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
18
States / cities
Los Angeles, California • San Francisco, California • Stanford, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Sep 30, 2026, 7:46 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Single Dose Aminoglycosides for Acute Uncomplicated Cystitis in the Emergency Department Setting

NCT05702762
View directory record Official record
Conditions
Urinary Tract Infections
Interventions
Gentamicin, Standard of Care
Drug
Lead sponsor
Mercy Health Ohio
Other
Eligibility
18 Years and older · Female only
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2023 · Synced Sep 30, 2026, 7:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma

NCT00784823
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib 1 mg/m2, Bortezomib 1.3 mg/m2, Bortezomib 1.6 mg/m2, Melphalan
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 76 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Sep 30, 2026, 7:46 PM EDT
Recruiting Phase 4 Interventional

Colchicine's Effect on Inflammatory Markers

NCT07287345
View directory record Official record
Conditions
Colchicine, Inflammation in Cardiac Surgery, Post Operative Atrial Fibrillation, Inflammatory Markers, Colchicine Adverse Reaction
Interventions
Colchicine (Colcrys®), Placebo
Drug
Lead sponsor
Ayesha Ather
Other
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 30, 2026, 7:46 PM EDT
Completed Not applicable Interventional

The Effect of Higher Protein Dosing in Critically Ill Patients

NCT03160547
View directory record Official record
Conditions
Critical Illness, Malnutrition
Interventions
Usual Protein/Amino Acid Group, Higher Protein/Amino Acid Group
Other
Lead sponsor
Clinical Evaluation Research Unit at Kingston General Hospital
Other
Eligibility
18 Years and older
Enrollment
1,329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
21
States / cities
Phoenix, Arizona • Long Beach, California • Evanston, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Sep 30, 2026, 7:46 PM EDT
Completed Phase 2 Interventional Results available

Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases

NCT00309842
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelofibrosis, MDS, Refractory Anemia, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Non-Hodgkin's Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes
Interventions
filgrastim, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, umbilical cord blood transplantation, total-body irradiation
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
2
States / cities
Minneapolis, Minnesota • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Sep 30, 2026, 7:46 PM EDT
Terminated Phase 2 Interventional Results available

Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older

NCT01453088
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Melphalan, Bortezomib
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
60 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 30, 2026, 7:46 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies

NCT00943319
View directory record Official record
Conditions
Leukemia, Lymphoma, Myeloma
Interventions
Busulfan, Fludarabine, Campath, Stem Cell Transplant
Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Sep 30, 2026, 7:46 PM EDT
Completed Phase 1 Interventional

Phase I Trial of Combination of FOLFIRI and SOM 230

NCT01434069
View directory record Official record
Conditions
Gastrointestinal Tumor
Interventions
SOM230C LAR, FOLFIRI Infusion
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 24, 2015 · Synced Sep 30, 2026, 7:46 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Machine Learning and 3D Image-Based Modeling for Real-Time Body Weight and Body Composition Estimation During Emergency Medical Care: Study 2

NCT06646133
View directory record Official record
Conditions
Body Weights and Measures, Body Weight in the Overweight and Obese Class - I Population, Weight Estimation, Emergency Drug Dosing
Interventions
3D camera weight estimate, Standard methods of weight estimation
Diagnostic Test
Lead sponsor
Florida Atlantic University
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Sep 30, 2026, 7:46 PM EDT
Completed Phase 2 Interventional Results available

Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma

NCT03339349
View directory record Official record
Conditions
Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolus
Interventions
Enoxaparin
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Sep 30, 2026, 7:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Impact of Alternative Nicotine-Delivery Products on Combustible Cigarette Use

NCT04084210
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Juul Electronic cigarette, Very Low Nicotine Cigarettes, Active Nicotine Patch, Placebo Patch
Device · Other · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years and older
Enrollment
209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Sep 30, 2026, 7:46 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT

NCT00585182
View directory record Official record
Conditions
Obesity, Venous Thrombosis, Anticoagulants
Interventions
Enoxaparin 0.5 mg/kg once daily
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Sep 30, 2026, 7:46 PM EDT
Terminated Not applicable Interventional Results available

Busulfan and Cyclophosphamide Followed By ALLO BMT

NCT01685411
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Allopurinol, Keppra, Busulfan, Cyclophosphamide, Tacrolimus, Mycophenolate mofetil, Allogeneic hematopoietic stem cell transplant, Filgrastim, antithymocyte globulin
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 44 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Sep 30, 2026, 7:46 PM EDT
Completed Phase 2 Interventional Results available

Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

NCT00345865
View directory record Official record
Conditions
Lymphoma
Interventions
carmustine, cyclophosphamide, etoposide, peripheral blood stem cell transplantation, irradiation therapy, G-CSF, Cytarabine
Drug · Procedure · Radiation + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 75 Years
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Sep 30, 2026, 7:46 PM EDT
Not yet recruiting Phase 2 Interventional

CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation

NCT07808112
View directory record Official record
Conditions
Graft -Versus-host-disease
Interventions
Hematopoietic Cell Transplantation, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil (MMF), Axatilimab
Procedure · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 30, 2026, 7:46 PM EDT
Completed Phase 2 Interventional Results available

Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation

NCT03680092
View directory record Official record
Conditions
GVHD, Hematologic Neoplasms
Interventions
Cyclophosphamide, abatacept, Methotrexate, Tacrolimus
Drug
Lead sponsor
Dimitrios Tzachanis, MD PhD
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Sep 30, 2026, 7:46 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Study of Weekly Abraxane and RAD001 in Women With Locally Adv. or Metastatic Breast Ca

NCT00934895
View directory record Official record
Conditions
Breast Cancer
Interventions
everolimus, abraxane
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Camden, New Jersey • Hamilton, New Jersey • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Sep 30, 2026, 7:46 PM EDT
Completed Phase 2 Interventional Results available

Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)

NCT01490723
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
Rituximab, 111In Ibritumomab, Planar Scintigraphy Imaging, 90Y IbritumomabTiuxetan, Fludarabine, Bendamustine, Thymoglobulin, Tacrolimus, Methotrexate, Mycophenolate, G-CSF, Stem Cell Transplantation
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Sep 30, 2026, 7:46 PM EDT
Recruiting Phase 2 Interventional Results available

Early Initiation of Oral Therapy With Cyclosporine and Eltrombopag for Treatment Naive Severe Aplastic Anemia (SAA)

NCT04304820
View directory record Official record
Conditions
Severe Aplastic Anemia
Interventions
Eltrombopag, Cyclosporine, Horse-Anti-thymocyte-Globulin
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
3 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2033
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 30, 2026, 7:46 PM EDT
Terminated Phase 1 Interventional

Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD)

NCT01940796
View directory record Official record
Conditions
Graft-vs-Host Disease, GVHD
Interventions
Brentuximab Vedotin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 26, 2018 · Synced Sep 30, 2026, 7:46 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Allo HSCT for High Risk Hemoglobinopathies

NCT06872333
View directory record Official record
Conditions
Graft Failure, Sickle Cell Disease, Hemoglobinopathies
Interventions
Alemtuzumab, Total Body Irradiation, Cell Infusion, Thymoglobulin, Fludarabine, Busulfan, Cyclophosphamide, Sirolimus, Tacrolimus, Mycophenolate Mofetil, Plerixafor (mozobil)
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2032
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 30, 2026, 7:46 PM EDT
Completed Phase 1 Interventional

Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source

NCT02167958
View directory record Official record
Conditions
Leukemia, MDS, Myelofibrosis, Lymphoma
Interventions
Fludarabine, Cyclophosphamide, Mesna, Total Body Irradiation, Hematopoietic stem cell infusion, Tacrolimus, Mycophenolate, G-CSF
Drug · Radiation · Other
Lead sponsor
Rafic Farah, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Sep 30, 2026, 7:46 PM EDT